Form 8-K - Current report:
SEC Accession No. 0001558370-25-011304
Filing Date
2025-08-13
Accepted
2025-08-13 07:37:04
Documents
15
Period of Report
2025-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20250813x8k.htm   iXBRL 8-K 35963
2 EX-99.1 adap-20250813xex99d1.htm EX-99.1 334730
3 GRAPHIC adap-20250813xex99d1001.jpg GRAPHIC 10901
4 GRAPHIC adap-20250813xex99d1002.jpg GRAPHIC 4097
  Complete submission text file 0001558370-25-011304.txt   523962

Data Files

Seq Description Document Type Size
5 EX-101.SCH adap-20250813.xsd EX-101.SCH 3898
6 EX-101.LAB adap-20250813_lab.xml EX-101.LAB 15972
7 EX-101.PRE adap-20250813_pre.xml EX-101.PRE 10791
17 EXTRACTED XBRL INSTANCE DOCUMENT adap-20250813x8k_htm.xml XML 4914
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)